Literature DB >> 6502312

Anemia of prematurity: determinants of the erythropoietin response.

J A Stockman, J E Graeber, D A Clark, K McClellan, J F Garcia, R E Kavey.   

Abstract

This study was undertaken to determine the factors that are important in determining the erythropoietin response in low-birth-weight infants during the period of so-called anemia of prematurity. In the first weeks of life oxygen consumption in a group of 21 infants gradually increased as hemoglobin level fell. The magnitude of the erythropoietin response inversely varied with the central venous oxygen tension (P-vO2) (r = -0.55, P less than 0.001). When the P-vO2 declined to less than 30 torr, erythropoietin values were uniformly increased above the "normal" range (defined as the values associated with P-vO2 greater than 38 torr). Erythropoietin values varied inversely with hemoglobin but in general did not exceed the values observed for normal adult men. The erythropoietin values in the infants were remarkably lower at any given hemoglobin level when compared with those of older children with anemia resulting from bone marrow failure. In general, elevations of erythropoietin were seen when the hemoglobin concentration declined to less than 10.0 gm/dl. Change in heart rate did not appear to be a reliable indicator of the presence of anemia; rather, it correlated best with oxygen consumption.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502312     DOI: 10.1016/s0022-3476(84)80308-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  28 in total

1.  Serum erythropoietin concentrations in symptomatic infants during the anaemia of prematurity.

Authors:  J Meyer; A Sive; P Jacobs
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

2.  How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity.

Authors:  Ronald G Strauss
Journal:  Transfusion       Date:  2008-01-07       Impact factor: 3.157

3.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

Review 4.  Drug utilisation in preterm and term neonates.

Authors:  L Gortner
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 5.  Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity.

Authors:  Robin K Ohls
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Anaemia of prematurity: pathophysiology and treatment.

Authors:  Ronald G Strauss
Journal:  Blood Rev       Date:  2010-11       Impact factor: 8.250

7.  Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.

Authors:  S Fang; R A Sherwood; H R Gamsu; J T Marsden; T J Peters; A Greenough
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 8.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Authors:  Constance Tom Noguchi; Li Wang; Heather M Rogers; Ruifeng Teng; Yi Jia
Journal:  Expert Rev Mol Med       Date:  2008-12-01       Impact factor: 5.600

9.  Double blind trial of recombinant human erythropoietin in preterm infants.

Authors:  A J Emmerson; H J Coles; C M Stern; T C Pearson
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

10.  Weekly intravenous administration of recombinant human erythropoietin in infants with the anaemia of prematurity.

Authors:  D Beck; E Masserey; M Meyer; A Calame
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.